|
Paroxysmal nocturnal hemoglobinuria: Where we stand |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Paroxysmal nocturnal hemoglobinuria: Where are we going |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
May 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties |
Jun 2024 |
American Journal of Hematology |
Aplastic Anemia |
|
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study |
Jul 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
Aug 2020 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
Nov 2019 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision-making and treatment of myelodysplastic syndromes |
Dec 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
